QQ客服 官方微博 反馈留言

	Bortezomib-based chemotherapy reduces early mortality and improves outcomes in patients with ultra-high-risk light-chain amyloidosis: a retrospective case control study
	Shen, Kai-Ni; Zhang, Cong-Li; Tian, Zhuang; Feng, Jun; Wang, Yi-Ning; Sun, Jian; Zhang, Lu; Cao, Xin-Xin; Zhou, Dao-bin; Li, Jian
	2019
卷号	26期号:2页码:66-73
关键词	AL amyloidosis ultra-high-risk bortezomib early mortality overall survival
ISSN号	1350-6129
DOI	10.1080/13506129.2019.1594759
URL标识	查看原文
收录类别	SCIE ; PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6342113
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Shen, Kai-Ni,Zhang, Cong-Li,Tian, Zhuang,et al. Bortezomib-based chemotherapy reduces early mortality and improves outcomes in patients with ultra-high-risk light-chain amyloidosis: a retrospective case control study[J],2019,26(2):66-73.
APA	Shen, Kai-Ni.,Zhang, Cong-Li.,Tian, Zhuang.,Feng, Jun.,Wang, Yi-Ning.,...&Li, Jian.(2019).Bortezomib-based chemotherapy reduces early mortality and improves outcomes in patients with ultra-high-risk light-chain amyloidosis: a retrospective case control study.,26(2),66-73.
MLA	Shen, Kai-Ni,et al."Bortezomib-based chemotherapy reduces early mortality and improves outcomes in patients with ultra-high-risk light-chain amyloidosis: a retrospective case control study".26.2(2019):66-73.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。